Systemic anticoagulation in progressive chronic kidney disease and atrial fibrillation

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Patients with chronic kidney disease (CKD) have an elevated risk of atrial fibrillation (AF).
• The optimal use of systemic anticoagulants in CKD patients, particularly those with AF, remains uncertain, especially in advanced stages.
• Understanding the balance between thromboembolic and bleeding risks is crucial for managing these patients.

Purpose of the Study:

• To determine the prevalence of AF in patients with CKD.
• To evaluate the incidence of thromboembolic and bleeding events in CKD patients with and without AF.
• To assess the impact of systemic anticoagulation on these outcomes in the CKD population.

Main Methods:

• Retrospective observational cohort study design.
• Inclusion of 146 patients with chronic kidney disease (CKD) of diverse etiologies.
• Analysis of atrial fibrillation (AF) prevalence, systemic anticoagulant use, and incidence of thromboembolic and bleeding events across CKD stages.

Main Results:

• 43.8% of CKD patients had atrial fibrillation (AF), with similar prevalence across CKD stages.
• Thromboembolic events were infrequent in AF patients but common in late-stage CKD.
• AF patients experienced more bleeding events, particularly in CKD stage IV.

Conclusions:

• Systemic anticoagulation did not decrease thromboembolic events in CKD patients with AF.
• Increased bleeding complications were observed in CKD patients with AF, especially in advanced stages.
• Caution is advised regarding systemic anticoagulant use in CKD patients with AF, particularly in later disease stages.